Edition:
United States

MediciNova Inc (MNOV.OQ)

MNOV.OQ on NASDAQ Stock Exchange Global Market

10.90USD
16 Feb 2018
Change (% chg)

$0.07 (+0.65%)
Prev Close
$10.83
Open
$10.91
Day's High
$11.40
Day's Low
$10.76
Volume
126,492
Avg. Vol
60,321
52-wk High
$11.40
52-wk Low
$4.40

Chart for

About

Medicinova, Inc. is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029... (more)

Overall

Beta: -0.01
Market Cap(Mil.): ¥41,485.93
Shares Outstanding(Mil.): 36.10
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-MediciNova Announces Proposed Underwritten Public Offering

* MEDICINOVA ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

Feb 07 2018

BRIEF-Medicinova Announces Phase 2B Trial results in MN-166 (Ibudilast)

* MEDICINOVA ANNOUNCES MN-166 (IBUDILAST) DEMONSTRATED A 26 PCT REDUCTION IN CONFIRMED DISABILITY PROGRESSION IN THE SPRINT-MS PHASE 2B TRIAL IN PROGRESSIVE MS: POTENTIAL BEST-IN-DISEASE DRUG Source text for Eikon: Further company coverage:

Feb 01 2018

BRIEF-Medicinova Announces Positive Top-Line Results From Clinical Trial Of MN-166 (ibudilast) In ALS

* MEDICINOVA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THE CLINICAL TRIAL OF MN-166 (IBUDILAST) IN ALS

Dec 07 2017

BRIEF-Medicinova announces collaboration

* Medicinova announces collaboration with the U.S. Department Of Veterans Affairs and Oregon Health & Science University to evaluate MN-166 (ibudilast) in methamphetamine use disorder

Nov 09 2017

BRIEF-Medicinova announces positive top-line results from the Sprint-MS Phase 2B trial of MN-166 (ibudilast)

* Medicinova announces positive top-line results from the Sprint-MS phase 2B trial of MN-166 (ibudilast) in progressive MS: achieved both primary endpoints including a significant reduction in whole brain atrophy and safety and tolerability

Oct 26 2017

BRIEF-Medicinova Inc files for potential mixed ‍​shelf of up to $200 million

* Medicinova Inc files for potential mixed ‍​shelf of up to $200 million - SEC filing Source text: [http://bit.ly/2fgDO2R] Further company coverage:

Sep 22 2017

BRIEF-MediciNova completes enrollment in the phase 2 trial of MN-166 in methamphetamine dependence

* MediciNova announces the completion of enrollment in the phase 2 clinical trial of MN-166 (ibudilast) in methamphetamine dependence

Sep 19 2017

Earnings vs. Estimates